The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.
Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.
Request a sample to get extensive insights into the Antiviral Combination Therapies Market
Companies in the antiviral combination therapies market are taking giant strides by increasing their trails to combat COVID-19. The Indian Institute of Chemical Technology (IICT) has joined forces with the Indian subsidiary of global pharmaceutical company, Mylan, to innovate in combination therapies for coronavirus. Many pharmaceutical companies in India have entered the Phase 3 of clinical trials with the help of computational modelling of molecules and laboratory-based data. The unprecedented demand for antiviral drugs has fueled innovations in combination therapy trials. Moreover, rising COVID-19 cases in India is acting as a key driver for market growth.
Medical institutes are increasing efforts to collaborate with hospitals to innovate in combination therapy trials. It has been found that the combination of antiviral drugs with antibiotics holds promising potentials in minimizing coronavirus symptoms in patients.
The antiviral combination therapies market is projected to advance at a high CAGR during the assessment period. Healthcare companies are exploring new therapy avenues such as the combined therapy of traditional Chinese medicine (TCM), along with antiviral drugs for the treatment of chronic hepatitis B (CHB). The Chinese YinQiSanHuang-antiviral decoction with entecavir is gaining popularity for reducing the annual incidence of liver fibrosis/cirrhosis amongst hepatitis B patients. Thus, analysts of Transparency Market Research (TMR) anticipate that the antiviral combination therapy is a fast growing phenomenon for hepatitis B treatment.
It has been found that conventional antiviral drugs alone are not enough for the efficacious hepatitis B treatment. As such, there is a need for credible clinical evidence to understand the combination of TCM and Western medicines for the hepatitis B treatment.
The combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported for the treatment of hepatitis B. As such, there is a need for clarification on clinical evidence to analyze the long-term efficacy of this type of combination therapy for CHB. Hepatitis B patients with low hepatitis B surface antigen (HBsAg) levels are being recommended with the combination therapy. However, the scientific community is faced with challenges such as restrictions in research project funds, which breaks the long-term continuity of trial periods. Hence, companies in the antiviral combination therapies market should increase their research expenditure to explore new combination therapies based on different mechanisms.
New drug developments are in pipeline for companies in the antiviral combination therapies market. In November 2018, Gilead Sciences— the U.S. biopharmaceutical company, announced that combination of GS-9688— an investigational oral selective small molecule agonist and oral antivirals is well tolerated among viral hepatitis patients.
To understand how our report can bring difference to your business strategy, Ask for a brochure
North America is predicted to account for the lion’s share in revenue of the antiviral combination therapies market during 2020-2030. However, adults living with HIV (Human Immunodeficiency Virus) have been reported to encounter adverse effects such as metabolic complications and kidney dysfunction due to the adoption of the combination antiretroviral therapy (ART). Hence, healthcare companies are increasing their R&D efforts to develop new ARV regimens that cause fewer serious and intolerable adverse effects than regimens used in the past.
NRTIs (Nucleoside Reverse Transcriptase Inhibitors) are associated with multiple mechanisms of action among HIV patients. Companies in the antiviral combination therapies market such as Merck are keen on development of their Islatravir NRTI. Manufacturers are increasing the availability of NRTIs that have greater inhibitory quotients against drug-resistant mutations. Such manufacturers have a competitive edge in the market since traditional NRTIs confer low fold-shifts in potency.
PEG IFN and Nucleoside Analogues Combination Enhances Immune Response in CHB Patients
Chronic hepatitis B is found to be an important cause for cirrhosis and hepatocellular carcinoma (HCC) worldwide. In order to avoid incidence of HCC, companies in the antiviral combination therapies market are increasing the availability of nucleoside analogues or pegylated interferon in order to prevent progression to cirrhosis. As such, antiviral combination therapy is being highly publicized as an additive and a synergistic agent to prevent HCC in hepatitis B patients. Hence, companies in the antiviral combination therapies market are increasing research to identify the sequence of treatments that can be efficacious in minimizing HCC in CHB patients.
Combinations of nucleoside analogues and PEG IFN bode well for preventing progression of cirrhosis in hepatitis B patients. Healthcare companies are capitalizing on incremental opportunities, since PEG IFN and nucleoside analogues result in lowering hepatitis B surface antigen (HBsAg) concentrations and enhancing immune response.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Antiviral Combination Therapies Market
Analysts’ Viewpoint
Anti-HIV combination drugs are gaining popularity for fighting COVID-19. Combination strategies involving PEG IFN and nucleoside analogues help to inhibit hepatitis B virus replication in patients, whilst enhancing immune response. Investigational small molecule agonists are being used with oral antivirals to advance in clinical trials for viral hepatitis.
Traditional Chinese medicine in combination with entecavir holds promising potentials for the hepatitis B treatment. However, antiviral medicines such as tenofovir or lamivudine are not recommended during the treatment. Hence, companies in the antiviral combination therapies market should increase awareness about the adverse effects of drugs to avoid morbidity and mortality in hepatitis B patients.
Antiviral Combination Therapies Market – Segmentation
|
Drug Combination |
|
|
Type |
|
|
Indication |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
Region |
|
Antiviral combination therapies market to reach valuation of US$ 71.4 Bn by 2030
Antiviral combination therapies market is driven by increase in investment in R&D for the development of combination medications that aid in fighting antiviral resistance
The integrase inhibitor/NRTI segment is projected to account for a major share of the global antiviral combination therapies market during the forecast period
North America accounted for a major share of the global antiviral combination therapies market in terms of revenue in 2019 and the trend is anticipated to continue during the forecast period
Key players in the global antiviral combination therapies market include Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antiviral Combination Therapies Market
4. Market Overview
4.1. Definition
4.2. Market Indicators
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030
4.5. Global Antiviral Combination Therapies Market Outlook
5. Key Insights
5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.2. Major Selling Antiviral Combination Drugs
5.3. Patent Information of Combination Therapies
5.4. Pipeline Analysis
5.5. Key Industry Events
5.6. Disease Epidemiology
6. Global Antiviral Combination Therapies Market Analysis and Forecast, by Drug Combination
6.1. Introduction
6.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination
6.3. Global Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
6.3.1. NRTI/NNRTI
6.3.2. Integrase Inhibitor/NRTI
6.3.3. NRTI
6.3.4. NRTI/Protease Inhibitor
6.3.5. Others
6.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination
7. Global Antiviral Combination Therapies Market Analysis and Forecast, by Type
7.1. Introduction
7.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Type
7.3. Global Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
7.3.1. Branded
7.3.2. Generic
7.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type
8. Global Antiviral Combination Therapies Market Analysis and Forecast, by Indication
8.1. Introduction
8.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Indication
8.3. Global Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
8.3.1. HIV
8.3.2. Hepatitis
8.3.3. Others
8.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication
9. Global Antiviral Combination Therapies Market Analysis and Forecast, by Route of Administration
9.1. Introduction
9.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration
9.3. Global Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
9.3.1. Oral
9.3.2. Intravenous
9.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration
10. Global Antiviral Combination Therapies Market Analysis and Forecast, by Distribution Channel
10.1. Introduction
10.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel
10.3. Global Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Others
10.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel
11. Global Antiviral Combination Therapies Market Analysis and Forecast, by Region
11.1. Regional Outlook
11.2. Introduction
11.3. Global Antiviral Combination Therapies Market Value Forecast, by Region
11.3.1. North America
11.3.2. Europe
11.3.3. Asia Pacific
11.3.4. Latin America
11.3.5. Middle East & Africa
11.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region
12. North America Antiviral Combination Therapies Market Analysis and Forecast
12.1. Key Findings
12.2. North America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
12.2.1. NRTI/NNRTI
12.2.2. Integrase Inhibitor/NRTI
12.2.3. NRTI
12.2.4. NRTI/Protease Inhibitor
12.2.5. Others
12.3. North America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
12.3.1. Branded
12.3.2. Generic
12.4. North America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
12.4.1. HIV
12.4.2. Hepatitis
12.4.3. Others
12.5. North America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
12.5.1. Oral
12.5.2. Intravenous
12.6. North America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Others
12.7. North America Antiviral Combination Therapies Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. North America Antiviral Combination Therapies Attractiveness Analysis
12.8.1. By Drug Combination
12.8.2. By Type
12.8.3. By Indication
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Antiviral Combination Therapies Market Analysis and Forecast
13.1. Key Findings
13.2. Europe Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
13.2.1. NRTI/NNRTI
13.2.2. Integrase Inhibitor/NRTI
13.2.3. NRTI
13.2.4. NRTI/Protease Inhibitor
13.2.5. Others
13.3. Europe Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
13.3.1. Branded
13.3.2. Generic
13.4. Europe Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
13.4.1. HIV
13.4.2. Hepatitis
13.4.3. Others
13.5. Europe Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
13.5.1. Oral
13.5.2. Intravenous
13.6. Europe Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Others
13.7. Europe Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. U.K.
13.7.2. Germany
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Europe Antiviral Combination Therapies Market Attractiveness Analysis
13.8.1. By Drug Combination
13.8.2. By Type
13.8.3. By Indication
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Antiviral Combination Therapies Market Analysis and Forecast
14.1. Key Findings
14.2. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
14.2.1. NRTI/NNRTI
14.2.2. Integrase Inhibitor/NRTI
14.2.3. NRTI
14.2.4. NRTI/Protease Inhibitor
14.2.5. Others
14.3. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
14.3.1. Branded
14.3.2. Generic
14.4. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
14.4.1. HIV
14.4.2. Hepatitis
14.4.3. Others
14.5. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
14.5.1. Oral
14.5.2. Intravenous
14.6. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Others
14.7. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. China
14.7.2. India
14.7.3. Japan
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis
14.8.1. By Drug Combination
14.8.2. By Type
14.8.3. By Indication
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Antiviral Combination Therapies Market Analysis and Forecast
15.1. Key Findings
15.2. Latin America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
15.2.1. NRTI/NNRTI
15.2.2. Integrase Inhibitor/NRTI
15.2.3. NRTI
15.2.4. NRTI/Protease Inhibitor
15.2.5. Others
15.3. Latin America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
15.3.1. Branded
15.3.2. Generic
15.4. Latin America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
15.4.1. HIV
15.4.2. Hepatitis
15.4.3. Others
15.5. Latin America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
15.5.1. Oral
15.5.2. Intravenous
15.6. Latin America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Others
15.7. Latin America Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Latin America Antiviral Combination Therapies Market Attractiveness Analysis
15.8.1. By Drug Combination
15.8.2. By Type
15.8.3. By Indication
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Antiviral Combination Therapies Market Analysis and Forecast
16.1. Key Findings
16.2. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030
16.2.1. NRTI/NNRTI
16.2.2. Integrase Inhibitor/NRTI
16.2.3. NRTI
16.2.4. NRTI/Protease Inhibitor
16.2.5. Others
16.3. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030
16.3.1. Branded
16.3.2. Generic
16.4. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030
16.4.1. HIV
16.4.2. Hepatitis
16.4.3. Others
16.5. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030
16.5.1. Oral
16.5.2. Intravenous
16.6. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Others
16.7. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis
16.8.1. By Drug Combination
16.8.2. By Type
16.8.3. By Indication
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company, 2019
17.3. Company Profiles
17.3.1. Celltrion, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Strategic Overview
17.3.1.5. SWOT Analysis
17.3.2. GlaxoSmithKline plc
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Strategic Overview
17.3.2.5. SWOT Analysis
17.3.3. Gilead Sciences, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Strategic Overview
17.3.3.5. SWOT Analysis
17.3.4. AbbVie, Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Strategic Overview
17.3.4.5. SWOT Analysis
17.3.5. Bristol-Myers Squibb Company
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Strategic Overview
17.3.5.5. SWOT Analysis
17.3.6. Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Strategic Overview
17.3.6.5. SWOT Analysis
17.3.7. Cipla, Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Strategic Overview
17.3.7.5. SWOT Analysis
17.3.8. Mylan N.V.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Strategic Overview
17.3.8.5. SWOT Analysis
17.3.9. Merck & Co., Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Strategic Overview
17.3.9.5. SWOT Analysis
17.3.10. F. Hoffmann-La Roche Ltd.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Strategic Overview
17.3.10.5. SWOT Analysis
List of Tables
Table 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 02: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 03: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 04: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 05: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 09: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 10: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 11: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 12: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 15: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 16: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 17: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 18: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 21: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 22: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 23: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 24: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 27: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 28: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 29: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 30: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030
Table 33: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 34: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 35: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 36: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Antiviral Combination Therapies Market Value Share, by Drug Combination, 2019
Figure 03: Global Antiviral Combination Therapies Market Value Share, by Type, 2019
Figure 04: Global Antiviral Combination Therapies Market Value Share, by Indication, 2019
Figure 05: Global Antiviral Combination Therapies Market Value Share, by Route of Administration, 2019
Figure 06: Global Antiviral Combination Therapies Market Value Share, by Distribution Channel, 2019
Figure 07: Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 08: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 09: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/NNRTI, 2018–2030
Figure 10: Global Antiviral Combination Therapies Market Value (US$ Mn), by Integrase Inhibitor/NRTI, 2018–2030
Figure 11: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI, 2018–2030
Figure 12: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/Protease Inhibitor, 2018–2030
Figure 13: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030
Figure 14: Global Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 15: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 16: Global Antiviral Combination Therapies Market Value (US$ Mn), by Branded, 2018–2030
Figure 17: Global Antiviral Combination Therapies Market Value (US$ Mn), by Generic, 2018–2030
Figure 18: Global Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 19: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 20: Global Antiviral Combination Therapies Market Value (US$ Mn), by HIV, 2018–2030
Figure 21: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hepatitis, 2018–2030
Figure 22: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030
Figure 23: Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 24: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 25: Global Antiviral Combination Therapies Market Value (US$ Mn), by Oral, 2018–2030
Figure 26: Global Antiviral Combination Therapies Market Value (US$ Mn), by Intravenous, 2018–2030
Figure 27: Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 28: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 29: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 30: Global Antiviral Combination Therapies Market Value (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 31: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030
Figure 32: Global Antiviral Combination Therapies Market Value Share Analysis, by Region, 2019 and 2030
Figure 33: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region
Figure 34: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 35: North America Antiviral Combination Therapies Market Value Share Analysis, by Country, 2019 and 2030
Figure 36: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Country, 2020–2030
Figure 37: North America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 38: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 39: North America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 40: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 41: North America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 42: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 43: North America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 44: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 45: North America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 46: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 47: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 48: Europe Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 49: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 50: Europe Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 51: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 52: Europe Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 53: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 54: Europe Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 55: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 56: Europe Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 57: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 58: Europe Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 59: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 60: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 61: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 62: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 63: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 64: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 65: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 66: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 67: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 68: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 69: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 70: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 71: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 72: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 73: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 74: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 75: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 76: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 77: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 78: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 79: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 80: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 81: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 82: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 83: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 84: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 85: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 86: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 87: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 88: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 89: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
Figure 90: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030
Figure 91: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
Figure 92: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030
Figure 93: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
Figure 94: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030
Figure 95: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 96: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 97: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 98: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 99: Global Antiviral Combination Therapies Market - Company Share Analysis (2019)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Antiviral Combination Therapies Market
